Hertfordshire, United Kingdom

Mario G Fsadni

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Mario G Fsadni in the Treatment of Dry Eye Syndrome

Introduction

Mario G Fsadni is an accomplished inventor based in Hertfordshire, GB. He has made significant contributions to the field of ophthalmology, particularly in the treatment of dry eye syndrome. With a total of 2 patents, his work focuses on innovative formulations that enhance the delivery of estrogen and its analogs for therapeutic purposes.

Latest Patents

Mario G Fsadni's latest patents include groundbreaking formulations for the topical application of estrogen and estrogen receptor modulators. These formulations are designed to treat primary or secondary dry eye syndrome, also known as keratoconjunctivitis sicca (KCS). The preferred formulations utilize 17-β-estradiol and its derivatives, delivered in lipid, liposomes, polymers, or aqueous and non-aqueous vehicles. These time-release and micro-dose formulations are particularly effective for the ocular surface tissues and may also benefit patients undergoing post-operative refractive surgery and corneal transplants.

Career Highlights

Throughout his career, Mario has worked with notable companies such as Altos Vision Limited and Redwood Pharma AB. His experience in these organizations has allowed him to develop and refine his innovative approaches to treatment.

Collaborations

Mario G Fsadni has collaborated with esteemed colleagues, including Clive H Reading and Thomas L Rowe. These partnerships have contributed to the advancement of his research and the successful development of his patented formulations.

Conclusion

Mario G Fsadni's contributions to the treatment of dry eye syndrome through innovative formulations highlight his expertise and dedication to improving patient care. His work continues to pave the way for advancements in ophthalmic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…